Multiple cytotoxic factors involved in IL-21 enhanced antitumor function of CIK cells signaled through STAT-3 and STAT5b pathways

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 10, 2013, Pages 5825-5831

  Rajbhandary, S ^a   Zhao, Ming Feng ^a   Zhao, Nan ^a   Lu, Wen Yi ^a   Zhu, Hai Bo ^a   Xiao, Xia ^a   Deng, Qi ^a   Li, Yu Ming ^a  

^a TIANJIN FIRST CENTRAL HOSPITAL   (China)

Author keywords

Antitumor function; Cytokine induced killer cells; Interleukin 21

Indexed keywords

ANTINEOPLASTIC AGENT; CD3 ANTIGEN; CD56 ANTIGEN; GAMMA INTERFERON; GRANZYME; INTERLEUKIN 21; INTERLEUKIN DERIVATIVE; KLRK1 PROTEIN, HUMAN; MESSENGER RNA; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; PERFORIN; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN; STAT5 PROTEIN; STAT5B PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA;

CELL SURVIVAL; CYTOKINE INDUCED KILLER CELL; GENETICS; HUMAN; K562 CELL LINE; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTIGENS, CD3; ANTIGENS, CD56; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CYTOKINE-INDUCED KILLER CELLS; GRANZYMES; HUMANS; INTERFERON-GAMMA; INTERLEUKINS; K562 CELLS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PERFORIN; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84890525812     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.10.5825     Document Type: Article

References (33)

1. Allard EL, Hardy MP, Leignadier J, et al (2007). Over expression of IL-21 promotes massive CD8+ memory T cell accumulation. Eur J Immunol, 37, 3069-77.
2. Brandt K, Bulfone-Paus S, Jenckel A, et al (2003). Interleukin-21 inhibits dendritic cell-mediated T cell activation and induction of contact hypersensitivity in vivo. J Invest Dermatol, 121, 1379-82.
3. Burchill MA, Goetz CA, Prlic M, et al (2003). Distinct Effects of STAT5 Activation on CD4+ and CD8+ T Cell Homeostasis: Development of CD4+CD25+ Regulatory T Cells versus CD8+ Memory T Cells. J Immunol, 171, 5853-64.
4. Burgess SJ, Marusina AI, Pathmanathan I, Borrego F, Coligan JE (2006). IL-21 down-regulates NKG2D/DAP10 expression on human NK and CD8+ T cells. J Immunol, 176, 1490-7.
5. Davis ID, Brady B, Kefford RF, et al (2009). Clinical and biological efficacy of recombinant human interleukin21 in patients with stage IVmalignant melanoma without prior treatment:a phase IIa trial. Clin Cancer Res, 15, 2123-9.
6. Decker T, Bogner C, Oelsner M, Peschel C, Ringshausen I (2010). Antiapoptotic effect of interleukin-2 in B-CLL cells with low and high affinity IL-2 receptors. AnnHematol, 89, 1125-32.
7. Gattinoni L, KlebanoffCA, Restifo NP (2012). Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer, 12, 71-84.
8. Golay J, Manganini M, Facchinetti V, et al (2003). Rituximabmediated antibody dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica, 88, 1002-12.
9. Gowda A, Roda J, Hussain SR, et al (2008). IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. Blood, 111, 4723-30.
10. Hand TW, Cui W, Jung YW, et al (2010). Differential effects of STAT5 and PI3K/AKT signaling on effector and memory CD8 T-cell survival. Proc Natl Acad Sci U S A, 107, 16601-6.
11. Kasaian MT, Whitters MJ, Carter LL, et al (2002). IL-21 Limits NK Cell Responses and Promotes Antigen-Specific T Cell Activation. Immunity, 16, 559-69.
12. Kortylewski M, Kujawski M, Wang T, et al (2005). Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med, 11, 1314-21.
13. Lee CK, Rao DT, Gertner R, et al (2000). Distinct requirements for IFNs and STAT1 in NK cell function. J Immunol, 165, 3571-7.
14. Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS (2005). A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant, 11, 181-7.
15. Moroz A, Eppolito C, Li Q, et al (2004). IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J Immunol, 173, 900-9.
16. Novy P, Huang X, Leonard WJ, Yang Y (2011). Intrinsic IL-21 signaling is critical for CD8 T cell survival and memory formation in response to vaccinia viral infection. J Immunol, 186, 2729-38.
17. Oh HM, Yu CR, Golestaneh N, et al (2011). STAT3 protein promotes T-cell survival and inhibits interleukin-2 production through up-regulation of Class O Forkhead transcription factors. J Biol Chem, 286, 30888-97.
18. Olioso P, Giancola R, Di Ritti M, et al (2009). Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol, 27, 130-9.
19. Ozaki K, Spolski R, Ettinger R, et al (2004). Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol, 173, 5361-71.
20. Parmigiani A, Pallin MF, Schmidtmayerova H, Lichtenheld MG, Pahwa S (2011). IL-21 and cellular activation concurrently induce potent cytotoxic function and promote antiviral activity in human CD8 T cells. Hum Immunol, 72, 115-23.
21. Parrish-Novak J, Dillon SR, Nelson A, et al (2000). Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature, 408, 57-63.
22. Pievani A, Borleri G, Pende D, et al (2011). Dual-functional capability of CD3+CD56+CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood, 18, 3301-10.
23. Quigley M, Huang X, Yang Y (2008). STAT1 signaling in CD8 T cells is required for their clonal expansion and memory formation following viral infection in vivo. J Immunol, 180, 2158-64.
24. Rankin AL, MacLeod H, Keegan S, et al (2011). IL-21 receptor is critical for the development of memory B cell responses. J Immunol, 186, 667-74.
25. Strengell M, Matikainen S, Sirén J, et al (2003). IL-21 in synergy with IL-15 or IL-18 enhances IFN-Y production in Human NK and T cells. J Immunol, 170, 5464-9.
26. Timmerman JM. Byrd JC, Andorsky DJ, et al (2012). Efficacy and safety of recombinant interleukin-21 (rIL-21) and rituximab in relapsed/refractory indolent lymphoma. Clin Cancer Res, 18, 5752-60.
27. Thompson JA, Curti BD, Redman BG, et al (2008). Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol, 26, 2034-9.
28. Verneris MR, Karami M, Baker J, Jayaswal A, Negrin RS (2004). Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood, 103, 3065-72.
29. Welte T, Zhang SS, Wang T, et al (2003). STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity. Proc Natl Acad Sci U S A, 100, 1879-84.
30. Yi JS, Du M, Zajac AJ (2009). A vital role for interleukin-21 in the control of a chronic viral infection. Science, 324, 1572-6.
31. Yue FY, Lo C, Sakhdari A, et al (2010). HIV-specific IL-21 producing CD4+ T cells are induced in acute and chronic progressive HIV infection and are associated with relative viral control. J Immunol, 185, 498-506.
32. Zeng R, Spolski R, Casas E, et al (2007). Mechanism of IL-21 mediated proliferation. Blood, 109, 4135-42.
33. Zhao MF, Deng Q, Li YM, et al (2007). Interleukin 21 enhances the expansion and anti-tumor cytotoxic activity of cytokineinduced killer cells derived from both peripheral blood and cord blood in vitro. Blood, 110, 4887b.